Human fibrinogen concentrate is used for congenital afibrinogenaemia and dysfibrinogenaemia states for treatment of bleeding complications. It is also used in acquired hypofibrinogenemia conditions such as massive haemorrhage, acquired coagulopathy, liver disease with bleeding and in obstetric haemorrhage. The product should be licensed for these clinical indications and approved by the HPRA. Fibrinogen, in presence of thrombin, activates FVIII and calcium, which is necessary to convert fibrinogen into stable three-dimensional fibrin coagula. The IBTS is responsible for the distribution of fibrinogen to users nationwide. IBTS must therefore have a sufficient stock and a stable supply of fibrinogen concentrates to meet patient needs.
Deadline
The time limit for receipt of tenders was 2023-07-28.
The procurement was published on 2023-06-13.
Contract notice (2023-06-13) Contracting authority Name and addresses
Name: Irish Blood Transfusion Service
Postal address: National Blood Centre , James’s Street
Postal town: Dublin
Postal code: D08 NH5R
Country: Ireland 🇮🇪
Contact person: Brian Boland
E-mail: brian.boland@ibts.ie📧
Region: Éire/Ireland🏙️
URL: https://www.etenders.gov.ie🌏
Address of the buyer profile: https://www.etenders.gov.ie🌏 Information about joint procurement
The contract is awarded by a central purchasing body
Communication
Access to the procurement documents is restricted
Documents URL: https://www.etenders.gov.ie🌏
Participation URL: https://www.etenders.gov.ie🌏
Object Scope of the procurement
Title:
“Fibrinogen concentrate used for congenital afibrinogenaemia and dysfibrinogenaemia”
Products/services: Medicinal products for the blood, blood-forming organs and the cardiovascular system📦
Short description:
“Human fibrinogen concentrate is used for congenital afibrinogenaemia and dysfibrinogenaemia states for treatment of bleeding complications. It is also used...”
Short description
Human fibrinogen concentrate is used for congenital afibrinogenaemia and dysfibrinogenaemia states for treatment of bleeding complications. It is also used in acquired hypofibrinogenemia conditions such as massive haemorrhage, acquired coagulopathy, liver disease with bleeding and in obstetric haemorrhage. The product should be licensed for these clinical indications and approved by the HPRA. Fibrinogen, in presence of thrombin, activates FVIII and calcium, which is necessary to convert fibrinogen into stable three-dimensional fibrin coagula. The IBTS is responsible for the distribution of fibrinogen to users nationwide. IBTS must therefore have a sufficient stock and a stable supply of fibrinogen concentrates to meet patient needs.
Human fibrinogen concentrate is used for congenital afibrinogenaemia and dysfibrinogenaemia states for treatment of bleeding complications. It is also used in acquired hypofibrinogenemia conditions such as massive haemorrhage, acquired coagulopathy, liver disease with bleeding and in obstetric haemorrhage. The product should be licensed for these clinical indications and approved by the HPRA. Fibrinogen, in presence of thrombin, activates FVIII and calcium, which is necessary to convert fibrinogen into stable three-dimensional fibrin coagula. The IBTS is responsible for the distribution of fibrinogen to users nationwide. IBTS must therefore have a sufficient stock and a stable supply of fibrinogen concentrates to meet patient needs.
Show more Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
Duration of the contract, framework agreement or dynamic purchasing system
The time frame below is expressed in number of months.
Description
Duration: 36
Duration of the contract, framework agreement or dynamic purchasing system
This contract is subject to renewal ✅ Description
Description of renewals: As per RFT
Legal, economic, financial and technical information Economic and financial standing
Selection criteria as stated in the procurement documents
Technical and professional ability
Selection criteria as stated in the procurement documents
Procedure Type of procedure
Open procedure
Administrative information
Time limit for receipt of tenders or requests to participate: 2023-07-28
12:00 📅
Languages in which tenders or requests to participate may be submitted: English 🗣️
The time frame below is expressed in number of months.
Minimum time frame during which the tenderer must maintain the tender: 3
Conditions for opening of tenders: 2023-07-28
12:30 📅
Complementary information Information about recurrence
This is a recurrent procurement ✅
Estimated timing for further notices to be published: As per RFT
Information about electronic workflows
Electronic ordering will be used
Electronic invoicing will be accepted
Electronic payment will be used
Review body
Name: Irish Blood Transfusion Services
Postal address: National Blood Centre , James’s Street
Postal town: Dublin
Postal code: D08 NH5R
Country: Ireland 🇮🇪
E-mail: brian.boland@ibts.ie📧
Source: OJS 2023/S 115-355453 (2023-06-13)